KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 78 filers reported holding KINNATE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $310,187 | -44.5% | 221,514 | +20.1% | 0.00% | – |
| Q2 2023 | $558,862 | -79.9% | 184,443 | -58.6% | 0.00% | – |
| Q1 2023 | $2,783,681 | +105663.0% | 445,389 | +3.2% | 0.00% | – |
| Q4 2022 | $2,632 | -99.9% | 431,614 | +2.6% | 0.00% | -100.0% |
| Q3 2022 | $5,027,000 | -2.9% | 420,709 | +2.5% | 0.00% | 0.0% |
| Q2 2022 | $5,176,000 | +25.9% | 410,484 | +12.4% | 0.00% | 0.0% |
| Q1 2022 | $4,111,000 | -36.2% | 365,103 | +0.4% | 0.00% | 0.0% |
| Q4 2021 | $6,443,000 | -17.0% | 363,632 | +7.8% | 0.00% | 0.0% |
| Q3 2021 | $7,762,000 | +40.5% | 337,222 | +42.1% | 0.00% | 0.0% |
| Q2 2021 | $5,523,000 | -25.7% | 237,249 | -0.6% | 0.00% | 0.0% |
| Q1 2021 | $7,434,000 | +534.3% | 238,581 | +709.3% | 0.00% | – |
| Q4 2020 | $1,172,000 | – | 29,480 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |